The superiority of bivalent over monovalent booster vaccines

The superiority of bivalent over monovalent booster vaccines

The bivalent booster also showed an advantage in preventing COVID-19-related hospital admissions, with high vaccine effectiveness across both groups (0·10 [0·07–0·15]) compared with the monovalent vaccine effectiveness (0·84 [0·78–0·91]).4 In the post-pandemic era the world is entering, it is vital...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet infectious diseases 2023-12, Vol.23 (12), p.1324-1325
Hauptverfasser: Arbel, Ronen, Wolff-Sagy, Yael
Format: Artikel
Sprache:eng
Schlagworte:
Age groups
Asymptomatic
COVID-19
COVID-19 vaccines
Effectiveness
Hospitals
Infections
Infectious diseases
Pandemics
Patient admissions
Risk management
Risk reduction
Severe acute respiratory syndrome coronavirus 2
Vaccine efficacy
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The bivalent booster also showed an advantage in preventing COVID-19-related hospital admissions, with high vaccine effectiveness across both groups (0·10 [0·07–0·15]) compared with the monovalent vaccine effectiveness (0·84 [0·78–0·91]).4 In the post-pandemic era the world is entering, it is vital to understand the absolute benefit of vaccinations. The study did not show the absolute risk reduction to prevent COVID-19-related hospital admissions by age group, making it impossible to conclude whether vaccination with the bivalent booster as a fourth dose should be recommended to different age groups. [...]should we vaccinate individuals with hybrid immunity?
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(23)00424-3